This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wagner, J. A. Articles by Ertl, G. Search for Related Content PubMed PubMed Citation Articles by Wagner, J. A. Articles by Ertl, G.

EXPERIMENTAL STUDY

Endogenous cannabinoids mediate hypotension after experimental myocardial infarction

^a Department of Medicine, University of Würzburg, Würzburg, Germany
^b National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA

Manuscript received April 24, 2001; revised manuscript received August 15, 2001, accepted August 29, 2001.

^* Reprint requests and correspondence: Dr. Jens A. Wagner, Department of Medicine, University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany.
j.wagner{at}medizin.uni-wuerzburg.de

OBJECTIVES: We sought to determine whether endocannabinoids influence hemodynamic variables in experimental models of acute myocardial infarction (MI).

BACKGROUND: Hypotension and cardiogenic shock are common complications in acute MI. Cannabinoids are strong vasodilators, and endocannabinoids are involved in hypotension in hemorrhagic and septic shock.

METHODS: The early effect of left coronary artery ligation on hemodynamic variables was measured in rats pretreated with the selective cannabinoid₁ receptor (CB₁) antagonist SR141716A (herein referred to as SR, 6.45 µmol/kg body weight intravenously) or vehicle. Endocannabinoids produced in monocytes and platelets were quantified by liquid chromatography/mass spectrometry (LC/MS), and their effects on blood pressure and vascular reactivity were determined.

RESULTS: After MI, mean arterial pressure (MAP) dropped from 126 ± 2 mm Hg to 76 ± 3 mm Hg in control rats, whereas the decline in blood pressure was smaller (from 121 ± 3 mm Hg to 108 ± 7 mm Hg, p < 0.01) in rats pretreated with SR. SR increased the tachycardia that follows MI (change [] in heart rate [HR] = 107 ± 21 beats/min vs. 49 ± 9 beats/min in control rats, p < 0.05). The MI sizes were the same in control rats and SR-treated rats. Circulating monocytes and platelets isolated 30 min after MI only decreased MAP when injected into untreated rats (MAP = –20 ± 5 mm Hg), but not in SR-pretreated rats. The endocannabinoids anandamide and 2-arachidonyl glycerol were detected in monocytes and platelets isolated after MI, but not in cells from sham rats. Survival rates at 2 h after MI were 70% for control rats and 36% for SR-treated rats (p < 0.05). Endothelium-dependent arterial relaxation was attenuated in SR-treated rats (maximal relaxation: 44 ± 3% [p < 0.01] vs. 70 ± 3% in control rats) and further depressed by SR treatment (24 ± 5%, p < 0.01 vs. MI placebo).

CONCLUSIONS: Cannabinoids generated in monocytes and platelets contribute to hypotension in acute MI. Cannabinoid₁ receptor blockade restores MAP but increases 2-h mortality, possibly by impairing endothelial function.

Abbreviations and Acronyms   2-AG   2-arachidonyl glycerol   CB1   cannabinoid1 receptor   HR   heart rate   IV   intravenous   LC/MS   liquid chromatography/mass spectrometry   MAP   mean arterial pressure   MI   myocardial infarction   SNP   sodium nitroprusside

This article has been cited by other articles:

				B. Su, H. Dong, R. Ma, X. Zhang, Q. Ding, and L. Xiong Cannabinoid 1 receptor mediation of spinal cord ischemic tolerance induced by limb remote ischemia preconditioning in rats J. Thorac. Cardiovasc. Surg., December 1, 2009; 138(6): 1409 - 1416. [Abstract] [Full Text] [PDF]

				N. Defer, J. Wan, R. Souktani, B. Escoubet, M. Perier, P. Caramelle, S. Manin, V. Deveaux, M.-C. Bourin, A. Zimmer, et al. The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy FASEB J, July 1, 2009; 23(7): 2120 - 2130. [Abstract] [Full Text] [PDF]

				L.-s. Jiang, J. Pu, Z.-h. Han, L.-h. Hu, and B. He Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages Cardiovasc Res, March 1, 2009; 81(4): 805 - 813. [Abstract] [Full Text] [PDF]

				S. Batkai, P. Mukhopadhyay, J. Harvey-White, R. Kechrid, P. Pacher, and G. Kunos Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1689 - H1695. [Abstract] [Full Text] [PDF]

				P. Mukhopadhyay, S. Batkai, M. Rajesh, N. Czifra, J. Harvey-White, G. Hasko, Z. Zsengeller, N. P. Gerard, L. Liaudet, G. Kunos, et al. Pharmacological Inhibition of CB1 Cannabinoid Receptor Protects Against Doxorubicin-Induced Cardiotoxicity J. Am. Coll. Cardiol., August 7, 2007; 50(6): 528 - 536. [Abstract] [Full Text] [PDF]

				H. J. Buettner, C. Mueller, M. Gick, M. Ferenc, J. Allgeier, T. Comberg, K. D. Werner, C. Schindler, and F.-J. Neumann The impact of obesity on mortality in UA/non-ST-segment elevation myocardial infarction Eur. Heart J., July 2, 2007; 28(14): 1694 - 1701. [Abstract] [Full Text] [PDF]

				P. Pacher, S. Batkai, and G. Kunos The Endocannabinoid System as an Emerging Target of Pharmacotherapy Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462. [Abstract] [Full Text] [PDF]

				E. V. Gelfand and C. P. Cannon Rimonabant: A Cannabinoid Receptor Type 1 Blocker for Management of Multiple Cardiometabolic Risk Factors J. Am. Coll. Cardiol., May 16, 2006; 47(10): 1919 - 1926. [Abstract] [Full Text] [PDF]

				P. Pacher, S. Batkai, D. Osei-Hyiaman, L. Offertaler, J. Liu, J. Harvey-White, A. Brassai, Z. Jarai, B. F. Cravatt, and G. Kunos Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H533 - H541. [Abstract] [Full Text] [PDF]

				S. M. Gardiner, J. E. March, P. A. Kemp, and T. Bennett Involvement of CB1-receptors and {beta}-adrenoceptors in the regional hemodynamic responses to lipopolysaccharide infusion in conscious rats Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2280 - H2288. [Abstract] [Full Text] [PDF]

				S. Batkai, P. Pacher, Z. Jarai, J. A. Wagner, and G. Kunos Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H595 - H600. [Abstract] [Full Text] [PDF]

				P. Pacher, S. Batkai, and G. Kunos Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice J. Physiol., July 15, 2004; 558(2): 647 - 657. [Abstract] [Full Text] [PDF]

				J. Liu, S. Batkai, P. Pacher, J. Harvey-White, J. A. Wagner, B. F. Cravatt, B. Gao, and G. Kunos Lipopolysaccharide Induces Anandamide Synthesis in Macrophages via CD14/MAPK/Phosphoinositide 3-Kinase/NF-{kappa}B Independently of Platelet-activating Factor J. Biol. Chem., November 7, 2003; 278(45): 45034 - 45039. [Abstract] [Full Text] [PDF]

				M. L. Orliac, R. Peroni, S. M Celuch, and E. Adler-Graschinsky Potentiation of Anandamide Effects in Mesenteric Beds Isolated from Endotoxemic Rats J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 179 - 184. [Abstract] [Full Text] [PDF]